A U.K. study has found that a third vaccine booster generated a higher level of antibodies to COVID-19 variants 28 days after the third vaccination, compared to individuals who have only completed the Pfizer–BioNTech or the Oxford–AstraZeneca two-shot series (pdf). “It’s encouraging that a wide range of vaccines, using different technologies, show benefits as a third dose to either AstraZeneca or Pfizer,” stated Saul Faust, NIHR clinical research facility director at University Hospital Southampton NHS Foundation Trust. “That gives confidence and flexibility in developing booster programmes here in the UK and globally, with other factors like supply chain and logistics also in play,” Faust added. In the study, 2,878 participants over 30 years of age received a third booster at least 70 days after the primary series. Seven COVID-19 vaccines, and three with a half dose, were used as a third booster. These vaccines included AstraZeneca, Novavax, Pfizer–BioNTech, France’s Valneva, …